Preetesh Jain

Medicine · Health Sciences

47h-index7.6kcitations466works2.52yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(223), Chronic Lymphocytic Leukemia Research(213), CAR-T cell therapy research(62), Chronic Myeloid Leukemia Treatments(61), Radiomics and Machine Learning in Medical Imaging(54)

Publications466 total

Impact of Putative Cell of Origin on CD19+CAR-T Outcomes in Patients with Large B-cell Lymphoma
Transplantation and Cellular Therapy·2026
Outcomes of CD20 Bispecific Antibodies after CD19 CAR T-cell Therapy in mantle cell lymphoma: A Multicenter Analysis from the Collaborative U.S. Bispecific Consortium (CUBIC)
Transplantation and Cellular Therapy·2026
Baseline Physical Function Predicts Toxicity Outcomes after Chimeric Antigen Receptor T-cell Therapy in Non-Hodgkin Lymphoma
Transplantation and Cellular Therapy·2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma
Blood Advances·2025Open Access
Integrative profiling strategies to guide personalized therapy in mantle cell lymphoma: a pilot study
npj Precision Oncology·2025Open Access
Germline variants and their role in the pathogenesis of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) in adult lymphoma patients
Blood·2025
Impact of extranodal sites of lymphoma on clinical outcomes after CD19 CAR T cell therapy
Blood·2025Open Access
Trial in progress: Phase 2 trial of epcoritamab in combination with rituximab-mini CVP for older unfit/frail patients or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell lymphoma
Blood·2025
Long-term clinical outcomes from the smart start trial: Rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma
Blood·2025Open Access
Durable responses in the updated 2-year follow-up of patients from a single-center with Relapsed/Refractory peripheral T-cell lymphoma treated with golidocitinib
Blood·2025Open Access
Mortality outcomes compared to the general population among long-term Hodgkin lymphoma survivors: A population-based analysis
Blood·2025Open Access
Acalabrutinib plus rituximab followed by brexucabtagene autoleucel for frontline treatment of high-risk Mantle Cell Lymphoma: The window-3 clinical trial
Blood·2025
Prehabilitation prior to CAR T-cell therapy in non-Hodgkin lymphoma: Baseline physical function and toxicity outcomes
Blood·2025Open Access
Impact of putative cell of origin on CD19+CAR-T outcomes in patients with large B-cell lymphoma
Blood·2025Open Access
Phase II Trial of lenalidomide plus rituximab (R2) in previously untreated follicular lymphoma: 15-year follow up data from MDACC Trial
Blood·2025Open Access
A Phase II, single-center, single-arm study evaluating the safety and efficacy of golidocitinib in the management of newly diagnosed PTCL (GOLDEN Study)
Blood·2025
Association of CAR T cell kinetics with outcomes after standard of care brexucabtagene autoleucel for relapsed/refractory Mantle Cell Lymphoma
Blood·2025
Outcomes for Patients with Primary Thyroid Lymphoma Treated with Radiation Therapy
International Journal of Radiation Oncology*Biology*Physics·2025
Treatment and outcomes of progression of disease post–CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis
Blood Advances·2025· 1 citedOpen Access
TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma
Blood·2025· 4 citedOpen Access
page 1 of 24Next →

Frequent Co-authors

Michael Wang(20), Hagop M. Kantarjian(19), Susan O’Brien(16), Zeev Estrov(13), Farhad Ravandi(13), Jörge E. Cortes(13), Rashmi Kanagal‐Shamanna(13), William G. Wierda(12), Alessandra Ferrajoli(12), Jan A. Burger(12), Elias Jabbour(11), Michael J. Keating(10), Gautam Borthakur(10), Luis Fayad(10), Christopher R. Flowers(10), Nitin Jain(9), Naval Daver(8), Loretta J. Nastoupil(8), Jason R. Westin(8), Maria Badillo(8)